Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Common-Size Income Statement
Quarterly Data

Regeneron Pharmaceuticals Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net product sales 52.31 54.09 56.00 53.92 53.12 56.11 52.75 49.77 61.35 61.40 55.26 80.28 66.03 80.53 68.19 66.94 64.61 62.85 67.65 59.29 60.45 62.33 64.52
Collaboration revenue 44.62 42.96 40.28 39.89 42.77 41.69 43.58 46.49 35.78 36.53 41.57 17.98 31.10 18.58 29.83 27.97 28.47 26.30 28.90 34.47 34.51 33.00 30.53
Other revenue 3.07 2.95 3.72 6.19 4.11 2.19 3.67 3.74 2.87 2.07 3.17 1.74 2.87 0.90 1.98 5.09 6.91 10.85 3.46 6.23 5.03 4.67 4.95
Revenues 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Cost of goods sold -7.05 -7.27 -7.64 -8.93 -6.68 -6.09 -6.59 -8.85 -4.81 -5.22 -6.99 -16.39 -6.92 -10.50 -7.24 -7.41 -5.71 -5.25 -4.31 -5.00 -5.66 -3.46 -4.14
Cost of collaboration and contract manufacturing -6.15 -6.27 -6.15 -6.12 -6.30 -6.73 -7.88 -6.98 -6.01 -5.18 -6.66 -3.45 -6.21 -3.00 -4.94 -7.16 -6.23 -8.86 -7.58 -5.32 -5.40 -4.42 -6.33
Cost of revenues -13.20% -13.54% -13.79% -15.05% -12.98% -12.82% -14.47% -15.83% -10.82% -10.40% -13.66% -19.84% -13.13% -13.50% -12.18% -14.57% -11.94% -14.11% -11.89% -10.32% -11.06% -7.89% -10.47%
Gross profit 86.80% 86.46% 86.21% 84.95% 87.02% 87.18% 85.53% 84.17% 89.18% 89.60% 86.34% 80.16% 86.87% 86.50% 87.82% 85.43% 88.06% 85.89% 88.11% 89.68% 88.94% 92.11% 89.53%
Research and development -34.17 -33.83 -39.69 -34.28 -31.98 -34.37 -34.82 -30.55 -31.04 -27.80 -28.46 -14.90 -19.27 -13.90 -29.38 -30.73 -29.84 -36.99 -31.94 -31.49 -32.39 -54.21 -37.49
Acquired in-process research and development -1.51 -0.67 -0.23 -0.87 -2.97 0.00 -1.77 -0.88 0.00 -6.89 -0.95 -0.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Selling, general, and administrative -19.20 -21.39 -21.91 -21.48 -19.05 -20.65 -19.01 -19.34 -18.02 -16.67 -15.18 -11.30 -12.89 -8.07 -16.04 -12.53 -14.25 -17.84 -20.09 -27.05 -20.50 -21.58 -24.00
Other operating income (expense), net -0.22 -0.41 -0.49 0.01 0.01 0.02 0.02 0.19 1.56 0.61 0.68 0.32 -1.22 0.61 1.60 5.99 1.94 2.57 2.21 0.00 0.00 0.00 0.00
Income from operations 31.70% 30.15% 23.89% 28.33% 33.04% 32.19% 29.94% 33.59% 41.68% 38.85% 42.44% 53.31% 53.50% 65.14% 44.00% 48.17% 45.91% 33.63% 38.29% 31.15% 36.05% 16.32% 28.04%
Other income (expense), net 8.80 16.16 -1.10 5.62 0.52 2.70 -2.24 5.72 10.26 -4.68 -6.20 -2.47 -0.47 8.17 6.13 2.99 -1.24 13.94 -1.39 10.18 1.85 -4.29 4.31
Interest expense -0.37 -0.42 -0.51 -0.53 -0.53 -0.60 -0.57 -0.51 -0.52 -0.46 -0.46 -0.28 -0.41 -0.28 -0.58 -0.61 -1.15 -0.50 -0.33 -0.31 -0.38 -0.41 -0.45
Other income (expense) 8.43% 15.75% -1.61% 5.09% -0.01% 2.10% -2.81% 5.21% 9.74% -5.13% -6.66% -2.75% -0.89% 7.89% 5.55% 2.38% -2.39% 13.45% -1.72% 9.87% 1.46% -4.70% 3.86%
Income before income taxes 40.13% 45.90% 22.28% 33.42% 33.03% 34.29% 27.13% 38.80% 51.42% 33.71% 35.79% 50.56% 52.61% 73.03% 49.55% 50.54% 43.52% 47.07% 36.57% 41.01% 37.52% 11.62% 31.90%
Income tax (expense) benefit -4.10 -5.52 0.68 0.35 -3.06 -3.63 -1.27 -3.74 -6.61 -3.89 -2.95 -5.54 -5.34 -12.73 -5.45 -3.11 -6.81 -1.11 -2.41 -4.51 -4.83 -1.63 -4.97
Net income 36.03% 40.38% 22.96% 33.77% 29.97% 30.66% 25.86% 35.06% 44.81% 29.82% 32.83% 45.01% 47.27% 60.31% 44.10% 47.43% 36.71% 45.97% 34.16% 36.51% 32.69% 9.99% 26.94%

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Income from operations The net result for the period of deducting operating expenses from operating revenues. Regeneron Pharmaceuticals Inc. income from operations as a percentage of revenues increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Regeneron Pharmaceuticals Inc. income before income taxes as a percentage of revenues increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024.
Net income The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Regeneron Pharmaceuticals Inc. net income as a percentage of revenues increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024.